Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO]

Glioblastoma multiforme (GBM WHO IV) is the most common and aggressive primary brain tumor in adults, carrying a poor prognosis with a median survival of 12-16 months. The annual incidence is approximately 5 per 100,000 (roughly 600 cases annually in Poland), predominantly affecting individuals in their prime productive years. The standard of care consists of maximal safe resection followed by the Stupp protocol (60 Gy fractionated radiotherapy and temozolomide chemotherapy). Routine surgical management relies on contrast-enhanced MRI. Gross total resection (GTR) is defined as the complete re

Trial Details

NCT ID
NCT06466031
Phase
NA
Sponsor
Copernicus Memorial Hospital
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • MRI & PET fusion
  • MRI+T1C
Locations (sample)
  • Lodz, Łódź Voivodeship, Poland|51.77058,19.47395

Key Eligibility Criteria

  • Single macroscopic tumor focus with the appearance of glioblastoma multiforme on MRI with contrast - contrast-enhancing lesion, completely or with …
  • No history of cancer in other organs. No suspicious lesions on X-ray of the chest and abdomen (CT with contrast).
  • No clinical suspicion of brain abscess - no meningeal symptoms, signs of neuroinfection, fever, elevated inflammatory parameters.
  • Primary tumor, without neurosurgical, radiotherapy or oncology intervention. Prior tumor biopsy is allowed.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →